# A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

Source: https://onco.cc/trials/nct07229586/  
OnCo record `nct07229586` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Adebrelimab and Gemcitabine in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07229586 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 100 participants planned, started 2025-12-02 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-7367 Injection, SHR-1316 Injection, Paclitaxel for Injection and Gemcitabine Hydrochloride for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07229586
- Phase: 1/2
- Setting: A Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of SHR-7367 in Combination With Anti-tumor Agents in Subjects With Solid Tumors
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07229586: https://clinicaltrials.gov/study/NCT07229586

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07229586.json